Layer-by-layer nanoencapsulation of camptothecin with improved activity

Area of Science:

• Nanotechnology
• Materials Science
• Pharmacology

Background:

• Camptothecin is a potent anticancer drug with limited clinical use due to poor solubility and stability.
• Developing effective drug delivery systems is crucial for enhancing camptothecin's therapeutic efficacy and reducing side effects.

Purpose of the Study:

• To develop and characterize novel nanocapsules for camptothecin delivery.
• To evaluate the stability, drug release, and in vitro anticancer activity of camptothecin-loaded nanocapsules.

Main Methods:

• Washless layer-by-layer (LbL) assembly using heparin and poly(l-lysine)-poly(ethylene glycol) block copolymers.
• Surface modification with polyethylene glycol (PEG) to enhance stability and control drug release.
• Assessment of camptothecin stability at different pH values and in the presence of albumin.
• In vitro cytotoxicity studies against CRL2303 glioblastoma cells.

Main Results:

• 160 nm nanocapsules were successfully fabricated, encapsulating up to 60% camptothecin.
• PEGylation of nanocapsule surfaces improved colloidal stability in serum and prolonged drug release.
• LbL nanocapsules preserved the active camptothecin lactone form at pH 7.4, enhancing chemical stability.
• Formulations demonstrated triple the activity of free camptothecin against glioblastoma cells.

Conclusions:

• LbL nanocapsules represent a promising platform for stable and effective camptothecin delivery.
• The enhanced stability and activity of encapsulated camptothecin offer potential for improved glioblastoma therapy.
• Surface modification with PEG is key to achieving favorable pharmacokinetic and pharmacodynamic properties.